Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Diaceutics ( (GB:DXRX) ).
Diaceutics PLC has announced that trustees of its 2020 Employee Benefit Trust have purchased ordinary shares on behalf of key personnel under the company’s Share Incentive Plan. The company has matched these purchases with a 1:1 share award, utilizing unallocated shares previously issued. This move is part of a broader strategy to facilitate share trading and incentivize employees, potentially impacting shareholder calculations under FCA rules.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £195.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
More about Diaceutics
Diaceutics PLC is a leading technology and solutions provider to the pharma and biotech industry, offering an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services, enabled by their platform DXRX – The Diagnostics Network.
Average Trading Volume: 114,570
Technical Sentiment Signal: Buy
Current Market Cap: £109M
See more insights into DXRX stock on TipRanks’ Stock Analysis page.